Paper Details
- Home
- Paper Details
Effect of Switching to Brexpiprazole on Plasma Homovanillic Acid Levels and Antipsychotic-Related Side Effects in Patients with Schizophrenia or Schizoaffective Disorder.
Author: HorikoshiSho, IchinoseMizue, Kanno-NozakiKeiko, MiuraItaru, WatanabeKenya, YabeHirooki, YamamotoShinnosuke
Original Abstract of the Article :
Although switching antipsychotics is a common strategy in the treatment of schizophrenia, caution is needed because of the risk of worsening of psychosis, particularly when switching to a dopamine D2 partial agonist. Homovanillic acid (HVA), a dopamine metabolite, is thought to be a possible indicat...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053707/
データ提供：米国国立医学図書館（NLM）
Brexpiprazole: A New Oasis in the Desert of Antipsychotic Treatment
The treatment of schizophrenia is a complex and often challenging journey through a vast and unforgiving desert. Finding a safe and effective antipsychotic that minimizes side effects is a constant quest for researchers. This study investigates the effects of switching to brexpiprazole monotherapy from other antipsychotics, examining its impact on plasma homovanillic acid (HVA) levels and the occurrence of antipsychotic-related side effects. The researchers analyzed data from patients with schizophrenia, exploring the potential benefits of this treatment switch. Their findings suggest that brexpiprazole may offer a promising alternative, with a potential for improved tolerability and reduced side effects.
A New Oasis in the Desert: Brexpiprazole Offers Potential Benefits
The study found that switching to brexpiprazole was associated with changes in HVA levels and a potential reduction in antipsychotic-related side effects. These findings suggest that brexpiprazole may be a valuable alternative for patients seeking a more tolerable antipsychotic treatment option.
Navigating the Desert of Schizophrenia: Finding a Suitable Pathway
This research highlights the ongoing search for better, more tolerable treatment options for schizophrenia. By understanding the potential benefits of different antipsychotics, clinicians can work with their patients to find a treatment pathway that minimizes side effects and maximizes quality of life.
Dr. Camel's Conclusion
This study offers a ray of hope in the desert of schizophrenia treatment, suggesting that brexpiprazole may provide a more tolerable option for patients seeking a change in antipsychotic medication. By continuing to explore new treatment options and individualize care, we can work towards creating a brighter future for those navigating the challenging landscape of mental health.
Date :
- Date Completed n.d.
- Date Revised 2022-04-22
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.